BlackRock Inc (BLK)vsGlaxoSmithKline PLC ADR (GSK)
BLK
BlackRock Inc
$1,084.83
+1.60%
FINANCIAL SERVICES · Cap: $165.75B
GSK
GlaxoSmithKline PLC ADR
$50.41
-0.18%
HEALTHCARE · Cap: $101.38B
Smart Verdict
WallStSmart Research — data-driven comparison
GlaxoSmithKline PLC ADR generates 28% more annual revenue ($32.78B vs $25.64B). BLK leads profitability with a 24.4% profit margin vs 17.8%. GSK appears more attractively valued with a PEG of 0.50. BLK earns a higher WallStSmart Score of 78/100 (B+).
BLK
Strong Buy78
out of 100
Grade: B+
GSK
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for BLK.
Margin of Safety
-3.1%
Fair Value
$56.71
Current Price
$50.41
$6.30 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 35.6%
Large-cap with strong market position
Keeps 24 of every $100 in revenue as profit
Revenue surging 27.0% year-over-year
Earnings expanding 45.9% YoY
Growing faster than its price suggests
Every $100 of equity generates 41 in profit
Strong operational efficiency at 36.3%
Large-cap with strong market position
Attractively priced relative to earnings
Areas to Watch
Moderate valuation
Weak financial health signals
Negative free cash flow — burning cash
1.5% revenue growth
Elevated debt levels
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : BLK
The strongest argument for BLK centers on Operating Margin, Market Cap, Profit Margin. Profitability is solid with margins at 24.4% and operating margin at 35.6%. Revenue growth of 27.0% demonstrates continued momentum.
Bull Case : GSK
The strongest argument for GSK centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 17.8% and operating margin at 36.3%. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bear Case : BLK
The primary concerns for BLK are P/E Ratio, Piotroski F-Score, Free Cash Flow.
Bear Case : GSK
The primary concerns for GSK are Revenue Growth, Debt/Equity, Altman Z-Score.
Key Dynamics to Monitor
BLK profiles as a growth stock while GSK is a value play — different risk/reward profiles.
BLK carries more volatility with a beta of 1.46 — expect wider price swings.
BLK is growing revenue faster at 27.0% — sustainability is the question.
GSK generates stronger free cash flow (698M), providing more financial flexibility.
Bottom Line
BLK scores higher overall (78/100 vs 66/100), backed by strong 24.4% margins and 27.0% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BlackRock Inc
FINANCIAL SERVICES · ASSET MANAGEMENT · USA
BlackRock, Inc. is an American multinational investment management corporation based in New York City.
GlaxoSmithKline PLC ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
Compare with Other ASSET MANAGEMENT Stocks
Want to dig deeper into these stocks?